Post-transplantation Cyclophosphamide, Tacrolimus and Low-Dose ATG as GVHD Prophylaxis for Allogeneic Peripheral Stem Cell Transplantation for Adult Patients With Lymphoid Malignancies: A Single Arm Phase II Study

Jie-Ling Jiang, Wen-Hui Gao, Li-Ning Wang, Ming Wan, Ling Wang, Jiong Hu, Jie-Ling Jiang, Wen-Hui Gao, Li-Ning Wang, Ming Wan, Ling Wang, Jiong Hu

Abstract

The PT-Cy was considered as one of the mainstay protocol for graft verus host disease (GVHD) prophylaxis. Recent study demonstrated that PT-Cy combined with other immunosuppressants could further reduce the incidence of GVHD and improve the GVHD and relapse free survival (GRFS). In this prospective phase II study, we evaluated the effect of a new GVHD prophylaxis consist of PT-Cy combined with tacrolimus and low dose anti-thymoglobulin (ATG). A total of 23 patients were enrolled including 20 patients with acute lymphoblastic leukemia (ALL) and three patients with T cell lymphoma. The median age was 29 years (range, 16~58 years). Patients with HLA-matched related donor (MSD, n=7) received PT-Cy combined with tacrolimus, while patients with HLA matched unrelated (MUD, n = 2) or haplo-identical (Haplo, n = 14) donor received additional ATG at 2.5 mg/kg on day 15 or day 22 after engraftment of neutrophils. As to the acute GVHD (aGVHD), only three patients developed grade I (n = 1) or grade II (n = 2) aGVHD with 100-day incidence of all aGVHD and II-IV aGVHD at 13.0 ± 5.1% and 9.1 ± 6.1% respectively. Only two patients had mild and one had moderate chronic GVHD (cGVHD), with 1-year incidence of cGVHD and moderate/severe cGVHD at 15.2 ± 8.7% and 4.6 ± 4.4% respectively. A high incidence of CMV reactivation was documented (14/16 with MUD/Haplo donor and 2/7 with MSD) with only 1 CMV disease documented. There were two EBV reactivation without post-transplantation lymphoproliferative disease (PTLD) documented. With a median follow-up of 303 days (range, 75~700 days), three patients relapsed leading to 1-year cumulative incidence of relapse (CIR) at 12.8 ± 9.2%. Only one patient died of CMV pneumonia on day 91 with both 100-day and 1-year non-relapse mortality (NRM) at 4.6 ± 4.4%. The 1-year overall survival (OS), event-free survival (EFS) and GRFS were 95.5 ± 4.4%, 82.6 ± 9.5%, and 68.0 ± 11.3% respectively. Based on Simon's stage II design, our primary data showed that the PT-Cy+tacrolimus ± ATG protocol was promising in preventing aGVHD and cGVHD, which may translate into low NRM without increased CIR. Further clinical trial with large number of patients should be warranted. This trial was registered at www.clinicaltrials.gov as #NCT04118075.

Keywords: allogeneic peripheral stem cell transplantation; anti-thymoglobulin; graft vs. host disease; lymphoid malignancies; post-transplantation cyclophosphamide.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Jiang, Gao, Wang, Wan, Wang and Hu.

Figures

Figure 1
Figure 1
Analysis of non-relapse mortality (NRM).
Figure 2
Figure 2
Kaplan-Meier analysis of overall survival (OS).
Figure 3
Figure 3
Kaplan-Meier analysis of event- free survival (EFS).
Figure 4
Figure 4
Kaplan-Meier analysis of GVHD and relapse-free survival (GRFS).

References

    1. Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol. (2018) 9:21–46. 10.1177/2040620717741860
    1. Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. (2010) 47:65–77. 10.1007/s12026-009-8139-0
    1. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. (2008) 14:641–50. 10.1016/j.bbmt.2008.03.005
    1. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. . High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. (2010) 115:3224–30. 10.1182/blood-2009-11-251595
    1. Kanakry CG, Tsai HL, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA, et al. . Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. (2014) 124:3817–27. 10.1182/blood-2014-07-587477
    1. Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, et al. . Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA- matched mobilized blood cell transplantation. Blood. (2016) 127:1502–8. 10.1182/blood-2015-10-672071
    1. Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol. (2016) 53:90–7. 10.1053/j.seminhematol.2016.01.005
    1. McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, et al. . Comparable composite endpoints after HLA-matched and HLA- haploidentical transplantation with posttransplantation cyclophosphamide. Haematologica. (2017) 102:391–400.
    1. Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gülbaş Z, et al. . Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. (2017) 10:113. 10.3324/haematol.2016.144139
    1. Wang L, Wang L, Fan X, Tang W, Hu J. Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantationfor adult patients with lymphoid malignancies: a prospective single-arm phase II study. Front Med. (2020) 15:108–15. 10.1007/s11684-019-0730-8
    1. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. . Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. (2018) 11:40-49. 10.1186/s13045-018-0586-4
    1. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. (1974) 18:295-304. 10.1097/00007890-197410000-00001
    1. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. (2015) 21:389–401.e1. 10.1016/j.bbmt.2015.02.025
    1. Jung SH, Lee TY, Kim KM, George S. Admissible two-stage designs for phase II cancer clinical trials. Stat Med. (2004) 23:561–69. 10.1002/sim.1600
    1. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. (1999) 18:695-706. 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>;2-O
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. (1958) 53:457-80. 10.1080/01621459.1958.10501452
    1. Mussetti A, Greco R, Peccatori J, Corradini P. Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? Expert Rev Hematol. (2017) 10:479–92. 10.1080/17474086.2017.1318054
    1. Montoro J, Piñana JL, Hernández-Boluda JC, Hernani R, Lorenzo I, Pérez A, et al. . Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplant. (2020) 55:2147–59. 10.1038/s41409-020-0921-6
    1. Marani C, Raiola AM, Morbelli S, Dominietto A, Ferrarazzo G, Avenoso D, et al. . Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Biol Blood Marrow Transplant. (2018) 24:2501–08. 10.1016/j.bbmt.2018.07.025
    1. El-Cheikh J, Devillier R, Dulery R, Massoud R, Al Chami F, Ghaoui N, et al. . Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. (2020) 20:617–23. 10.1016/j.clml.2020.04.003
    1. Peric Z, Mohty R, Bastos J, Brissot E, Battipaglia G, Belhocine R, et al. . Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies. Bone Marrow Transplant. (2020) 55:763–72. 10.1038/s41409-019-0726-7
    1. Esquirol A, Pascual MJ, Ortiz M, Piñana JL, Ferra C, Garcia Cadenas I, et al. . Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. Bone Marrow Transplant. (2017) 52:1273–79. 10.1038/bmt.2017.111
    1. Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, et al. . Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Biol Blood Marrow Transplant. (2017) 23:459-66. 10.1016/j.bbmt.2016.12.636
    1. Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, et al. . Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. (2019) 106:212–9. 10.1016/j.ejca.2018.11.003
    1. Czerw T, Labopin M, Giebel S, Socié G, Volin L, Fegueux N, et al. . Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. Cancer. (2018) 124:2523-33. 10.1002/cncr.31354
    1. Huntley D, Giménez E, Pascual MJ, Remigia MJ, Amat P, Vázquez L, et al. . Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. Bone Marrow Transplant. (2020) 55:1347–56. 10.1038/s41409-020-0865-x
    1. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. . Letermovir prophylaxis for cytomegalovirus in hematopoietic cell transplantation. N Engl J Med. (2017) 377:2433–44. 10.1056/NEJMoa1706640

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit